🇺🇸 FDA
Pipeline program

Sevasemten

EDG-5506-203

Phase 2 small_molecule active

Quick answer

Sevasemten for Becker Muscular Dystrophy is a Phase 2 program (small_molecule) at Edgewise Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Edgewise Therapeutics
Indication
Becker Muscular Dystrophy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials